All News Active Biotech AB

Equities

ACTI

SE0001137985

Delayed Nasdaq Stockholm Other stock markets 05:25:33 2024-04-23 am EDT			5-day change	1st Jan Change
0.56 ^SEK	+0.18%		-1.58%	+22.67%

Apr. 03	Active Biotech AB Announces Start of Enrollment to the Clinical Phase I Biodistribution Study with Laquinimod Eye Drops	CI
Feb. 08	Active Biotech AB Reports Earnings Results for the Fourth Quarter Ended December 31, 2023	CI

All News

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Annual Report 2023 Active Biotech AB (publ)	Apr. 22	AQ
Active Biotech announces start of enrollment to the clinical phase I biodistribution study with laquinimod eye drops	Apr. 03	AQ
Active Biotech AB Announces Start of Enrollment to the Clinical Phase I Biodistribution Study with Laquinimod Eye Drops	Apr. 03	CI
Active Biotech Q4 2023 - Three Externally Funded Trials in 2024	Feb. 09	AQ
Active Biotech Year End Report 2023	Feb. 08	AQ
Active Biotech AB Reports Earnings Results for the Fourth Quarter Ended December 31, 2023	Feb. 08	CI
Active Biotech AB Reports Earnings Results for the Full Year Ended December 31, 2023	Feb. 08	CI
Number of shares and votes in Active Biotech	Dec. 29	AQ
Active Biotech provides update on the scheduled clinical program for 2024	Dec. 22	AQ
Active Biotech AB Provides Update on the Scheduled Clinical Program for 2024	Dec. 22	CI
Positive preclinical tasquinimod data presented at ASH 2023 now available on Active Biotech’s website	Dec. 14	AQ
Active Biotech Raises SEK44 Million via Rights Offering	Dec. 06	MT
Active Biotech announces outcome of the Company’s rights issue	Dec. 06	AQ
Active Biotech Teams Up with US Research Group on Clinical Study of Laquinimod Eye Drops	Dec. 06	MT
Active Biotech enters into collaboration agreement for clinical ocular biodistribution study with laquinimod	Dec. 05	AQ
Active Biotech's nomination committee appointed	Dec. 01	AQ
Active Biotech AB Appoints Mats Arnhög and Petter Wingstrand to Nomination Committee	Dec. 01	CI
Lead Principal Investigator Rebekka Schneider-Kramann presents the clinical plan and positioning of tasquinimod in myelofibrosis	Dec. 01	AQ
Management and members of the board of directors have subscribed for shares in Active Biotech’s ongoing rights issue	Nov. 29	AQ
Rights Issue: 3 new shares @ 0.45 SEK for 7 existing shares	Nov. 14	FA

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

All News Active Biotech AB

Equities

ACTI

SE0001137985

All News

Filters